Company Quick10K Filing
UFP Technologies
Price40.63 EPS2
Shares7 P/E22
MCap304 P/FCF14
Net Debt4 EBIT18
TEV308 TEV/EBIT18
TTM 2019-09-30, in MM, except price, ratios
10-Q 2020-03-31 Filed 2020-05-08
10-K 2019-12-31 Filed 2020-03-13
10-Q 2019-09-30 Filed 2019-11-08
10-Q 2019-06-30 Filed 2019-08-09
10-Q 2019-03-31 Filed 2019-05-10
10-K 2018-12-31 Filed 2019-03-15
10-Q 2018-09-30 Filed 2018-11-09
10-Q 2018-06-30 Filed 2018-08-09
10-Q 2018-03-31 Filed 2018-05-10
10-K 2017-12-31 Filed 2018-03-16
10-Q 2017-09-30 Filed 2017-11-09
10-Q 2017-06-30 Filed 2017-08-09
10-Q 2017-03-31 Filed 2017-05-09
10-K 2016-12-31 Filed 2017-03-10
10-Q 2016-09-30 Filed 2016-11-09
10-Q 2016-06-30 Filed 2016-08-09
10-Q 2016-03-31 Filed 2016-05-09
10-K 2015-12-31 Filed 2016-03-11
10-Q 2015-09-30 Filed 2015-11-06
10-Q 2015-06-30 Filed 2015-08-07
10-Q 2015-03-31 Filed 2015-05-08
10-K 2014-12-31 Filed 2015-03-13
10-Q 2014-09-30 Filed 2014-11-07
10-Q 2014-06-30 Filed 2014-08-08
10-Q 2014-03-31 Filed 2014-05-12
10-K 2013-12-31 Filed 2014-03-14
10-Q 2013-09-30 Filed 2013-11-07
10-Q 2013-06-30 Filed 2013-08-08
10-Q 2013-03-31 Filed 2013-05-10
10-K 2012-12-31 Filed 2013-03-15
10-Q 2012-09-30 Filed 2012-11-09
10-Q 2012-06-30 Filed 2012-08-09
10-Q 2012-03-31 Filed 2012-05-10
10-K 2011-12-31 Filed 2012-03-15
10-Q 2011-09-30 Filed 2011-11-09
10-Q 2011-06-30 Filed 2011-08-10
10-Q 2011-03-31 Filed 2011-05-12
10-K 2010-12-31 Filed 2011-03-16
10-Q 2010-09-30 Filed 2010-11-12
10-Q 2010-06-30 Filed 2010-08-10
10-Q 2010-03-31 Filed 2010-05-14
10-K 2009-12-31 Filed 2010-03-30
8-K 2020-06-10
8-K 2020-05-05
8-K 2020-03-04
8-K 2020-02-24
8-K 2019-12-11
8-K 2019-11-15
8-K 2019-11-05
8-K 2019-08-26
8-K 2019-08-06
8-K 2019-06-10
8-K 2019-06-05
8-K 2019-05-07
8-K 2019-03-06
8-K 2019-02-19
8-K 2018-11-12
8-K 2018-11-01
8-K 2018-08-27
8-K 2018-08-02
8-K 2018-06-06
8-K 2018-05-04
8-K 2018-03-01
8-K 2018-02-21
8-K 2018-01-30

UFPT 10Q Quarterly Report

Part I: Financial Information
Item 1:Financial Statements
Item 2:Management's Discussion and Analysis of Financial Condition and Results of Operations
Item 4:Controls and Procedures
Part Ii:Other Information
Item 1A:Risk Factors
Item 2:Unregistered Sales of Equity Securities and Use of Proceeds
Item 6:Exhibits
EX-31.1 exh_311.htm
EX-31.2 exh_312.htm
EX-32.1 exh_321.htm

UFP Technologies Earnings 2020-03-31

Balance SheetIncome StatementCash Flow
205164123824102012201420172020
Assets, Equity
554433221102012201420172020
Rev, G Profit, Net Income
5024-2-28-54-802012201420172020
Ops, Inv, Fin

10-Q 1 f10q_050820p.htm FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark one)

 

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended     MARCH 31, 2020    

 

OR

 

[  ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _________ to _________

 

Commission File Number: 001-12648

 

UFP Technologies, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware 04-2314970
(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)

 

100 Hale Street, Newburyport, MA 01950, USA

(Address of principal executive offices) (Zip Code)

 

(978) 352-2200

(Registrant's telephone number, including area code)

 

_________________________________________

(Former name, former address, and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock UFPT The NASDAQ Stock Market L.L.C.

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes  X ; No ____

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes  X ; No ____

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☒
Non-accelerated filer ☐ Smaller reporting company ☐
  Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ____; No  X

 

7,482,844 shares of registrant’s Common Stock, $0.01 par value, were outstanding as of May 1, 2020.

 

1

  

 

UFP Technologies, Inc.

 

Index

 

Page

 

PART I - FINANCIAL INFORMATION 3
Item 1. Financial Statements 3
Condensed Consolidated Balance Sheets as of March 31, 2020 and December 31, 2019 (unaudited) 3
Condensed Consolidated Statements of Income for the Three Months Ended March 31, 2020 and March 31, 2019 (unaudited) 4
Condensed Consolidated Statements of Stockholders’ Equity for the Three Months Ended March 31, 2020 and March 31, 2019 (unaudited) 5
Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2020 and March 31, 2019 (unaudited) 6
Notes to Interim Condensed Consolidated Financial Statements 7
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 17
Item 4. Controls and Procedures 22
PART II - OTHER INFORMATION 23
Item 1A. Risk Factors 23
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 24
Item 6. Exhibits 24
Signatures 25

 

 

 

2

  

 

PART I: FINANCIAL INFORMATION

 

ITEM 1:FINANCIAL STATEMENTS

 

UFP Technologies, Inc.

Condensed Consolidated Balance Sheets

(In thousands, except share data)

(Unaudited)

 

 

   March 31,
2020
  December 31,
2019
Assets          
Current assets:          
Cash and cash equivalents  $7,334   $3,743 
Receivables, less allowance of $541 at March 31, 2020 and $486 at December 31, 2019   29,449    28,648 
Inventories   20,242    18,276 
Prepaid expenses   2,750    2,304 
Refundable income taxes   -    279 
Total current assets   59,775    53,250 
Property, plant and equipment   117,292    116,089 
Less accumulated depreciation and amortization   (61,062)   (59,350)
Net property, plant and equipment   56,230    56,739 
Goodwill   51,838    51,838 
Intangible assets, net   20,661    20,975 
Non-qualified deferred compensation plan   2,790    2,775 
Operating lease right of use assets   2,771    3,034 
Other assets   148    147 
Total assets  $194,213   $188,758 
           
Liabilities and Stockholders’ Equity          
Current liabilities:          
Accounts payable  $7,535   $4,577 
Accrued expenses   6,350    8,483 
Deferred revenue   2,432    2,574 
Operating lease liabilities   1,140    1,150 
Income taxes payable   5    - 
Total current liabilities   17,462    16,784 
Deferred income taxes   5,342    4,921 
Non-qualified deferred compensation plan   2,817    2,788 
Operating lease liabilities   1,687    1,940 
Other liabilities   630    334 
Total liabilities   27,938    26,767 
Commitments and contingencies          
Stockholders’ equity:          
Preferred stock, $.01 par value, 1,000,000 shares authorized; no shares issued   -    - 
Common stock, $.01 par value, 20,000,000 shares authorized; 7,512,403 and 7,482,844 shares issued and outstanding, respectively at March 31, 2020;7,475,768 and 7,446,209 shares issued and outstanding, respectively at December 31, 2019   75    74 
Additional paid-in capital   31,344    30,952 
Retained earnings   135,443    131,552 
Treasury stock at cost, 29,559 shares at March 31, 2020 and December 31, 2019   (587)   (587)
Total stockholders’ equity   166,275    161,991 
Total liabilities and stockholders' equity  $194,213   $188,758 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

3

  

 

UFP Technologies, Inc.

Condensed Consolidated Statements of Income

(In thousands, except per share data)

(Unaudited)

 

   Three Months Ended
   March 31,
   2020  2019
Net sales  $48,277   $47,328 
Cost of sales   35,454    34,831 
Gross profit   12,823    12,497 
Selling, general and administrative expenses   7,752    7,244 
Gain on sale of fixed assets   (4)   - 
Operating income   5,075    5,253 
Interest expense   16    231 
Other expense   327    239 
Income before income tax expense   4,732    4,783 
Income tax expense   841    1,049 
Net income  $3,891   $3,734 
           
Net income per share:          
Basic  $0.52   $0.50 
Diluted  $0.52   $0.50 
Weighted average common shares outstanding:          
Basic   7,457    7,402 
Diluted   7,538    7,466 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

4

  

 

UFP Technologies, Inc.

Condensed Consolidated Statements of Stockholders’ Equity

(In thousands)

(Unaudited)

 

Three Months Ended March 31, 2020
         Additional           Total
   Common Stock  Paid-in  Retained  Treasury Stock  Stockholders'
   Shares  Amount  Capital  Earnings  Shares  Amount  Equity
                      
Balance at December 31, 2019   7,446   $74   $30,952   $131,552    30   $(587)  $161,991 
                                    
Share-based compensation   28    -    537    -    -    -    537 
Exercise of stock options   20    1    415    -    -    -    416 
Net share settlement of restricted stock units   (11)   -    (560)   -    -    -    (560)
Net income   -    -    -    3,891    -    -    3,891 
                                    
Balance at March 31, 2020   7,483   $75   $31,344   $135,443    30   $(587)  $166,275 

 

 

Three Months Ended March 31, 2019
         Additional           Total
   Common Stock  Paid-in  Retained  Treasury Stock  Stockholders'
   Shares  Amount  Capital  Earnings  Shares  Amount  Equity
                      
Balance at December 31, 2018   7,385   $74   $29,168   $111,802    30   $(587)  $140,457 
                                    
Share-based compensation   20    -    294    -    -    -    294 
Exercise of stock options   17    -    285    -    -    -    285 
Net share settlement of restricted stock units   (8)   -    (271)   -    -    -    (271)
Net income   -    -    -    3,734    -    -    3,734 
                                    
Balance at March 31, 2019   7,414   $74   $29,476   $115,536    30   $(587)  $144,499 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

5

  

 

UFP Technologies, Inc.

Condensed Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

 

   Three Months Ended
   March 31,
   2020  2019
Cash flows from operating activities:          
Net income  $3,891   $3,734 
Adjustments to reconcile net income to net cash provided by operating activities:          
Depreciation and amortization   2,066    2,022 
Gain on sale of fixed assets   (4)   - 
Share-based compensation   537    294 
Deferred income taxes   421    424 
Changes in operating assets and liabilities:          
Receivables, net   (801)   (1,451)
Inventories   (1,966)   139 
Prepaid expenses   (446)   364 
Refundable income taxes   284    781 
Other assets   247    (338)
Accounts payable   2,726    (907)
Accrued expenses   (2,133)   (2,506)
Deferred revenue   (142)   465 
Non-qualified deferred compensation plan and other liabilities   62    608 
Net cash provided by operating activities   4,742    3,629 
Cash flows from investing activities:          
Additions to property, plant, and equipment   (1,020)   (1,388)
Proceeds from sale of fixed assets   13    - 
Net cash used in investing activities   (1,007)   (1,388)
Cash flows from financing activities:          
Payments on revolving line of credit   -    (3,000)
Proceeds from exercise of stock options   416    285 
Payment of statutory withholdings for restricted stock units vested   (560)   (271)
Net cash used in financing activities   (144)   (2,986)
Net increase (decrease) in cash and cash equivalents   3,591    (745)
Cash and cash equivalents at beginning of period   3,743    3,238 
Cash and cash equivalents at end of period  $7,334   $2,493 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

6

  

 

Notes to Interim Condensed Consolidated Financial Statements

 

(1)Basis of Presentation

 

The interim condensed consolidated financial statements of UFP Technologies, Inc. (the “Company”) presented herein, have been prepared pursuant to the rules of the Securities and Exchange Commission for quarterly reports on Form 10-Q and do not include all the information and note disclosures required by accounting principles generally accepted in the United States of America. These statements should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2019, included in the Company's 2019 Annual Report on Form 10-K, as filed with the Securities and Exchange Commission.

 

The condensed consolidated balance sheets as of March 31, 2020 and December 31, 2019, the condensed consolidated statements of income for the three-month periods ended March 31, 2020 and 2019, the condensed consolidated statements of stockholders’ equity for the three-month periods ended March 31, 2020 and 2019, and the condensed consolidated statements of cash flows for the three-month periods ended March 31, 2020 and 2019 are unaudited but, in the opinion of management, include all adjustments (consisting of normal, recurring adjustments) necessary for a fair presentation of results for these interim periods. The condensed consolidated balance sheet as of December 31, 2019 has been derived from the Company’s annual financial statements that were audited by an independent registered public accounting firm but does not include all of the information and footnotes required for complete audited financial statements.

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.

 

The results of operations for the three-month period ended March 31, 2020 are not necessarily indicative of the results to be expected for the entire fiscal year ending December 31, 2020.

 

Recent Accounting Pronouncements

 

In June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2016-13, Financial Instruments – Credit Losses (Accounting Standards Codification (ASC) 326). The Company adopted ASC 326 on January 1, 2020. See Note 4 for further details.

 

In January 2017, the FASB issued ASU 2017-04, Intangibles—Goodwill and Other (ASC 350), Simplifying the Test for Goodwill Impairment. The guidance removes Step 2 of the goodwill impairment test and eliminates the need to determine the fair value of individual assets and liabilities to measure goodwill impairment. A goodwill impairment will now be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. Entities will continue to have the option to perform a qualitative assessment to determine if a quantitative impairment test is necessary. The guidance will be applied prospectively and is effective for annual and interim goodwill impairment tests in fiscal years beginning after December 15, 2019. The Company adopted ASC 350 on January 1, 2020 and it did not have a material impact on its financial condition or results of operations.

 

Revisions

 

Certain revisions have been made to the December 31, 2019 Condensed Consolidated Balance Sheet to conform to the current year presentation relating to a reclassification of long-term operating lease liabilities to current operating lease liabilities. The reclassification resulted in an increase of current operating lease liabilities of $476 thousand and a decrease of long-term operating lease liabilities of $476 thousand. These revisions had no impact on previously reported earnings, net income or cash flows and are deemed immaterial to the previously issued financial statements.

 

7

  

 

(2)Revenue Recognition

 

The Company recognizes revenue when a customer obtains control of a promised good or service. The amount of revenue recognized reflects the consideration that the Company expects to be entitled to in exchange for promised goods or services. The Company recognizes revenue in accordance with the core principles of ASC 606 which include (1) identifying the contract with a customer, (2) identifying separate performance obligations within the contract, (3) determining the transaction price, (4) allocating the transaction price to the performance obligations, and (5) recognizing revenue. The Company recognizes all but an immaterial portion of its product sales upon shipment. The Company recognizes revenue from the sale of tooling and machinery primarily upon customer acceptance, with the exception of certain tooling where control does not transfer to the customer, resulting in revenue being recognized over the estimated time for which parts are produced with the use of each respective tool. The Company recognizes revenue from engineering services as the services are performed. The Company recognizes revenue from bill and hold transactions at the time the specified goods are complete and available to the customer. In the ordinary course of business, the Company accepts sales returns from customers for defective goods, such amounts being immaterial. Although only applicable to an insignificant number of transactions, the Company has elected to exclude sales taxes from the transaction price. The Company has elected to account for shipping and handling activities for which the Company is responsible under the terms and conditions of the sale not as performance obligations but rather as fulfillment costs. These activities are required to fulfill the Company’s promise to transfer the good and are expensed when revenue is recognized.

 

Disaggregated Revenue

 

The following table presents the Company’s revenue disaggregated by the major types of goods and services sold to our customers (in thousands):

 

   Three Months Ended
   March 31,
Net sales of:  2020  2019
Products  $47,029   $46,410 
Tooling and Machinery   677    645 
Engineering services   571    273 
Total net sales  $48,277   $47,328 

 

Contract balances

 

Timing of revenue recognition may differ from the timing of invoicing to customers. When invoicing occurs prior to revenue recognition, the Company has deferred revenue, or contract liabilities, included within “deferred revenue” on the condensed consolidated balance sheet.

 

The following table presents opening and closing balances of contract liabilities for the three months ended March 31, 2020 and 2019 (in thousands):

 

   Contract Liabilities
   Three Months Ended
March 31,
   2020  2019
Deferred revenue - beginning of period  $2,574   $2,507 
Increases due to consideration received from customers   525    991 
Revenue recognized   (667)   (526)
Deferred revenue - end of period  $2,432   $2,972 

 

Revenue recognized during the three months ended March 31, 2020 and 2019 from amounts included in deferred revenue at the beginning of the period was approximately $517 thousand and $497 thousand, respectively.

 

8

  

 

When invoicing occurs after revenue recognition, the Company has unbilled receivables (contract assets) included within “receivables” on the condensed consolidated balance sheet. The Company considered the guidance in ASC 326 upon adoption and in the current period and determined that an allowance for credit losses was not necessary on the unbilled receivables balance due to there being no history of credit losses. The following table presents opening and closing balances of contract assets for the three months ended March 31, 2020 and 2019 (in thousands):

 

   Contract Assets
   Three Months Ended
March 31,
   2020  2019
Unbilled Receivables - beginning of period  $72   $65 
Increases due to revenue recognized - not invoiced to customers   522    85 
Decreases due to customer invoicing   (404)   (106)
Unbilled Receivables - end of period  $190   $44 

 

(3)Supplemental Cash Flow Information

 

   Three Months Ended
   March 31,
   2020  2019
   (in thousands)
Cash paid for:          
Interest  $12   $47 
Income taxes, net of refunds  $-   $(156)
           
Non-cash investing and financing activities:          
Capital additions accrued but not yet paid  $232   $108 
Recognition of lease asset and liability  $-   $3,831 

 

(4)Allowance for Credit Losses

 

Effective January 1, 2020, the Company adopted ASU 2016-13, Financial Instruments – Credit Losses (ASC 326) which is required to be applied by means of a cumulative-effect adjustment to the opening retained earnings balance as of the adoption date. This ASU replaces the incurred loss impairment model with an expected credit loss impairment model for financial instruments, including trade receivables and contract assets. The amendment requires entities to consider forward-looking information to estimate expected credit losses, resulting in earlier recognition of losses for receivables that are current or not yet due, which were not considered under the previous accounting guidance. There was no impact to the Company’s opening retained earnings or its consolidated balance sheet upon adoption.

 

The Company is exposed to credit losses primarily through sales of products and services. The Company’s expected loss allowance methodology for accounts receivable is developed using historical collection experience, current and future economic and market conditions and a review of the current status of customers' trade accounts receivables. Due to the short-term nature of such receivables, the estimate of amount of accounts receivable that may not be collected is based on aging of the accounts receivable balances and the financial condition of customers. Additionally, specific allowance amounts are established to record the appropriate provision for customers that have a higher probability of default. The Company’s monitoring activities include timely account reconciliation, dispute resolution, payment confirmation, consideration of customers' financial condition and macroeconomic conditions. Balances are written off when determined to be uncollectible. The Company considered the current and expected future economic and market conditions surrounding the novel coronavirus ("COVID-19") pandemic and included specific allowance amounts for any customer determined to have been significantly impacted. Estimates are used to determine the allowance. It is based on assessment of anticipated payment and all other historical, current and future information that is reasonably available.

 

9

  

 

The following table provides a roll-forward of the allowance for credit losses that is deducted from the amortized cost basis of accounts receivable to present the net amount expected to be collected for the three months ended March 31, 2020 (in thousands):

 

   Allowance for Credit
Losses
   Three Months Ended
March 31, 2020
Allowance - beginning of period  $486 
Provision for expected credit losses   60 
Amounts written off against the allowance   (5)
Allowance - end of period  $541 

 

(5)Fair Value of Financial Instruments

 

Financial instruments recorded at fair value in the consolidated balance sheets, or disclosed at fair value in the footnotes, are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels defined by ASC 820, Fair Value Measurements and Disclosures, and directly related to the amount of subjectivity associated with inputs to fair valuation of these assets and liabilities, are as follows:

 

Level 1

Valued based on unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. An active market for the asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.

 

Level 2

Valued based on either directly or indirectly observable prices for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life.

 

Level 3

Valued based on management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.

 

The following table presents the fair value and hierarchy levels, for financial assets that are measured at fair value on a recurring basis (in thousands):

 

Level 2  March 31,
2020
  March 31,
2019
Liabilities:          
Derivative financial instruments  $(624)  $(175)

 

Derivative financial instruments consist of an interest rate swap for which fair value is determined through the use of a pricing model, that utilizes verifiable inputs such as market interest rates that are observable at commonly quoted intervals for the full term of the swap agreement.

 

The Company has financial instruments, such as accounts receivable, accounts payable, and accrued expenses, that are stated at carrying amounts that approximate fair value because of the short maturity of those instruments. The carrying amount of the Company’s long-term debt approximates fair value as the interest rate on the debt approximates the estimated borrowing rate currently available to the Company.

 

10

  

 

(6)Share-Based Compensation

 

Share-based compensation is measured at the grant date based on the fair value of the award and is recognized as an expense over the requisite service period (generally the vesting period of the equity grant).

 

The Company issues share-based awards through several plans that are described in detail in the notes to the consolidated financial statements for the year ended December 31, 2019. The compensation cost charged against income for those plans is included in selling, general & administrative expenses as follows (in thousands):

 

   Three Months Ended
   March 31,
Share-based compensation related to:  2020  2019
Common stock grants  $100   $100 
Stock option grants   60    7 
Restricted Stock Unit Awards ("RSUs")   377    187 
Total share-based compensation  $537   $294 

 

The total income tax benefit recognized in the condensed consolidated statements of income for share-based compensation arrangements was approximately $348 thousand and $164 thousand for the three-month periods ended March 31, 2020 and 2019, respectively.

 

The following is a summary of stock option activity under all plans for the three-month period ended March 31, 2020:

 

   Shares Under
Options
  Weighted
Average
Exercise Price

(per share)
  Weighted
Average
Remaining
Contractual
Life
(in years)
  Aggregate
Intrinsic
Value
(in thousands)
Outstanding at December 31, 2019   105,614   $25.34           
Granted   -                
Exercised   (19,586)  $21.20           
Outstanding at March 31, 2020   86,028   $26.28    5.70   $1,025 
Exercisable at March 31, 2020   65,742   $23.04    5.00   $989 
Vested and expected to vest at March 31, 2020   86,028   $26.28    5.70   $1,025 

 

During the three-month period ended March 31, 2020, the total intrinsic value of all options exercised (i.e., the difference between the market price on the exercise date and the price paid by the employees to exercise the options) was approximately $530 thousand, and the total amount of consideration received by the Company from the exercised options was approximately $415 thousand. During the three-month period ended March 31, 2019, the total intrinsic value of all options exercised was approximately $274 thousand, and the total amount of consideration received by the Company from the exercised options was approximately $285 thousand. At its discretion, the Company allows option holders to surrender previously owned common stock in lieu of paying the exercise price and withholding taxes. During both the three-month periods ended March 31, 2020 and 2019, no shares were surrendered for this purpose.

 

On February 24, 2020, the Company’s Compensation Committee approved the award of $400 thousand, payable in shares of common stock to the Company’s Chairman, Chief Executive Officer, and President under the 2003 Incentive Plan. Subject to his continued employment and the terms of his employment agreement, the shares will be issued in December 2020.

 

11

  

 

The following table summarizes information about RSU activity during the three-month period ended March 31, 2020:

 

   Restricted
Stock Units
  Weighted Average
Award Date
Fair Value
Outstanding at December 31, 2019   113,866   $28.36 
Awarded   42,733    49.96 
Shares vested   (28,244)   27.02 
Outstanding at March 31, 2020   128,355   $31.58 

 

At the Company’s discretion, upon vesting RSU holders are given the option to net-share settle to cover the required minimum withholding tax and the remaining amount is converted into the equivalent number of common shares and issued to the RSU holder. During the three-month periods ended March 31, 2020 and 2019, 11,195 and 8,132 shares were surrendered at an average market price of $49.99 and $33.35, respectively.

 

As of March 31, 2020, the Company had approximately $4.0 million of unrecognized compensation expense that is expected to be recognized over a period of 4 years.

 

(7)Inventories

 

Inventories are stated at the lower of cost (determined using the first-in, first-out method) or net realizable value, and consist of the following at the stated dates (in thousands):

 

   March 31,
2020
  December 31,
2019
Raw materials  $11,471   $10,540 
Work in process   2,795    2,279 
Finished goods   5,976    5,457 
Total inventory  $20,242   $18,276 

 

(8)Leases

 

The Company has operating leases for offices, manufacturing plants, vehicles and certain office and manufacturing equipment. Leases with an initial term of 12 months or less are not recorded on the balance sheet. The Company has elected the practical expedient to account for each separate lease component of a contract and its associated non-lease components as a single lease component, thus causing all fixed payments to be capitalized. The Company also elected the package of practical expedients permitted within the new standard, which among other things, allows the Company to carry forward historical lease classification. Variable lease payment amounts that cannot be determined at the commencement of the lease such as increases in lease payments based on changes in index rates or usage, are not included in the ROU assets or operating lease liabilities. These are expensed as incurred and recorded as variable lease expense. The Company determines if an arrangement is a lease at the inception of a contract. Operating lease ROU assets and operating lease liabilities are stated separately in the condensed consolidated balance sheet. 

 

ROU assets represent the Company's right to use an underlying asset during the lease term and operating lease liabilities represent the Company's obligation to make lease payments arising from the lease. ROU assets and operating lease liabilities are recognized at commencement date based on the net present value of fixed lease payments over the lease term. The Company's lease term includes options to extend or terminate the lease when it is reasonably certain that we will exercise that option. ROU assets will also be adjusted for any deferred or accrued rent. As the Company's operating leases do not typically provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. Operating fixed lease expense is recognized on a straight-line basis over the lease term.

 

12

  

 

   Three Months Ended
   March 31,
($'s in thousands)
   2020  2019
Lease Cost:          
Operating  $305   $307 
Variable   57    57 
Short-term   7    6 
Total lease cost  $369   $370 
           
Cash paid for amounts included in measurement of lease liabilities:          
Operating  $305   $303 
           
Weighted-average remaining lease term (years):          
Operating   2.45    3.37 
Weighted-average discount rate:          
Operating   4.45%   4.45%

 

The aggregate future lease payments for operating leases as of March 31, 2020 were as follows (in thousands):

 

Remainder of 2020  $874 
2021   1,121 
2022   959 
2023   36 
2024   - 
Thereafter   - 
Total lease payments   2,990 
Less: Interest   (163)
Present value of lease liabilities  $2,827 

 

(9)Income Per Share

 

Basic income per share is based on the weighted average number of shares of common stock outstanding. Diluted income per share is based upon the weighted average number of common shares outstanding and dilutive common stock equivalent shares outstanding during each period.

 

The weighted average number of shares used to compute basic and diluted net income per share consisted of the following (in thousands):

 

   Three Months Ended
   March 31,
   2020  2019
Basic weighted average common shares outstanding   7,457    7,402 
Weighted average common equivalent shares due to stock options and RSUs   81    64 
Diluted weighted average common shares outstanding   7,538    7,466 

 

 

13

  

 

The computation of diluted earnings per share excludes the effect of the potential exercise of stock options when the average market price of the common stock is lower than the exercise price of the related options during the period. These outstanding stock awards are not included in the computation of diluted income per share because the effect would be antidilutive. For both the three-month periods ended March 31, 2020 and 2019, the number of stock awards excluded from the computation of diluted earnings per share for this reason was zero.

 

(10)Segment Reporting

 

The Company consists of a single operating and reportable segment.

 

Revenues from customers outside of the United States are not material. No customer comprised more than 10% of the Company’s consolidated revenues for both the three-month periods ended March 31, 2020 and 2019. All of the Company’s assets are located in the United States.

 

The Company’s products are primarily sold to customers within the Medical, Automotive, Consumer, Aerospace and Defense, Industrial, and Electronics markets. Net sales by market for the three-month periods ended March 31, 2020 and 2019 are as follows (in thousands):

 

   Three Months Ended March 31,
   2020  2019 (1)
Market  Net Sales  %  Net Sales  %
             
Medical  $33,688    69.8%  $28,944    61.2%
Automotive   4,602    9.5%   5,738    12.1%
Consumer   3,439    7.1%   4,424    9.3%
Aerospace & Defense   2,711    5.6%   3,532    7.5%
Industrial   1,917    4.0%   2,485    5.3%
Electronics   1,920    4.0%   2,204    4.7%
Net Sales  $48,277    100.0%  $47,327    100.0%

 

(1)Certain amounts for the three months ended March 31, 2019 were reclassified between markets to conform to the current period presentation.

 

(11)Other Intangible Assets

 

The carrying values of the Company’s definite lived intangible assets as of March 31, 2020 are as follows (in thousands):

 

   Tradename
& Brand
  Non-
Compete
  Customer
List
  Total
Estimated useful life  10 years  5 years  20 years   
Gross amount  $367   $462   $22,555   $23,384 
Accumulated amortization   (80)   (200)   (2,443)   (2,723)
Net balance  $287   $262   $20,112   $20,661 

 

 

14

  

 

Amortization expense related to intangible assets was approximately $314 thousand for both the three-month periods ended March 31, 2020 and 2019. The estimated remaining amortization expense as of March 31, 2020 is as follows (in thousands):

 

Remainder of:   
2020  $943 
2021   1,257 
2022   1,257 
2023   1,172 
2024   1,164 
Thereafter   14,868 
Total  $20,661 

 

(12)Income Taxes

 

The income tax expense included in the accompanying unaudited condensed consolidated statements of income principally relates to the Company’s proportionate share of the pre-tax income of its wholly-owned subsidiaries. The determination of income tax expense for interim reporting purposes is based upon the estimated effective tax rate for the year, adjusted for the impact of any discrete items which are accounted for in the period in which they occur. The Company recorded tax expense of approximately 17.8% and 21.9% of income before income tax expense for the three-month periods ended March 31, 2020 and 2019, respectively.

 

(13)Indebtedness

 

On February 1, 2018, the Company, as the borrower, entered into an unsecured $70 million Amended and Restated Credit Agreement (the “Amended and Restated Credit Agreement”) with certain of the Company’s subsidiaries (the “Subsidiary Guarantors”) and Bank of America, N.A., in its capacity as the initial lender, Administrative Agent, Swingline Lender and L/C Issuer, and certain other lenders from time to time party thereto. The Amended and Restated Credit Agreement amends and restates the Company’s prior credit agreement.

 

The credit facilities under the Amended and Restated Credit Agreement (the “Amended and Restated Credit Facilities”) consist of a $20 million unsecured term loan and an unsecured revolving credit facility, under which the Company may borrow up to $50 million.  The Amended and Restated Credit Agreement matures on February 1, 2023.  The proceeds borrowed pursuant to the Amended and Restated Credit Agreement may be used for general corporate purposes, as well as permitted acquisitions. The Company’s obligations under the Amended and Restated Credit Agreement are guaranteed by the Subsidiary Guarantors.

 

The Amended and Restated Credit Agreement calls for interest of LIBOR plus a margin that ranges from 1.0% to 1.5% or, at the discretion of the Company, the bank’s prime rate less a margin that ranges from 0.25% to zero. In both cases the applicable margin is dependent upon Company performance.  Under the Amended and Restated Credit Agreement, the Company is subject to a minimum fixed-charge coverage financial covenant as well as a maximum total funded debt to EBITDA financial covenant.  The Amended and Restated Credit Agreement contains other covenants customary for transactions of this type, including restrictions on certain payments, permitted indebtedness and permitted investments. As of March 31, 2020 there were no amounts outstanding under the Amended and Restated Credit Facilities other than $0.7 million in standby letters of credit outstanding drawable as a financial guarantee on worker’s compensation insurance policies. As of March 31, 2020, the applicable interest rate was approximately 1.99% and the Company was in compliance with all covenants under the Amended and Restated Credit Agreement.

 

15

  

 

Derivative Financial Instruments

 

The Company uses interest-rate-related derivative instruments to manage its exposure related to changes in interest rates on its variable-rate debt instruments. The Company does not enter into derivative instruments for any purpose other than cash flow hedging. The Company does not speculate using derivative instruments. By using derivative financial instruments to hedge exposures to changes in interest rates, the Company exposes itself to credit risk and market risk. Credit risk is the failure of the counterparty to perform under the terms of the derivative contract. When the fair value of a derivative contract is positive, the counterparty owes the Company, which creates credit risk for the Company. When the fair value of a derivative contract is negative, the Company owes the counterparty and, therefore, the Company is not exposed to the counterparty’s credit risk. The Company minimizes counterparty credit risk in derivative instruments by entering into transactions with carefully selected major financial institutions based upon their credit profile. Market risk is the adverse effect on the value of a derivative instrument that results from a change in interest rates. The market risk associated with interest-rate contracts is managed by establishing and monitoring parameters that limit the types and degree of market risk that may be undertaken. The Company assesses interest rate risk by identifying and monitoring changes in interest rate exposures that may adversely impact expected future cash flows and by evaluating hedging opportunities. The Company’s debt obligations expose the Company to variability in interest payments due to changes in interest rates. The Company believes that it is prudent to limit the variability of a portion of its interest payments. To meet this objective, in connection with the term loan under the Amended and Restated Credit Agreement, the Company entered into a $20 million, 5-year interest rate swap agreement under which the Company receives three-month LIBOR plus the applicable margin and pays a 2.7% fixed rate plus the applicable margin. The swap agreement was established to modify the Company’s interest rate exposure by converting interest on the term loan from a variable rate to a fixed rate to hedge against the possibility of rising interest rates during the term of the loan. Because the Company repaid its term loan in full, the swap agreement no longer serves this purpose and may be canceled by the Company prior to its expiration date. The notional amount was approximately $13.6 million at March 31, 2020. The fair value of the swap as of March 31, 2020 and 2019 was approximately $(624) thousand and $(175) thousand, respectively and is included in other liabilities. Changes in the fair value of the swap are recorded in other expense and were approximately $300 thousand and $239 thousand during the three-months ended March 31, 2020 and 2019, respectively.

 

(14)Subsequent Events

 

The Company’s operations expose it to risks associated with the COVID-19 pandemic. Although the COVID-19 pandemic did not materially impact the Company’s first quarter results, it has since more significantly impacted the Company’s operations. While all of the Company’s factories are deemed essential, not all of its customers’ operations are essential and, therefore, demand for product, especially in the automotive and consumer markets, has been negatively impacted. Partially mitigating this are increased orders from certain customers in the medical market. The COVID-19 pandemic has also impacted the Company’s cost of manufacturing its goods, including higher labor costs, maintenance costs and manufacturing inefficiencies due to employee absenteeism and significantly enhanced cleaning and sterilization. With regard to the Company’s supply chain, there has thus far been minimal disruption in the availability of raw materials, as most of the Company’s major suppliers have also been deemed to be essential businesses. However, to mitigate risk, the Company has increased its purchases of raw materials to establish safety stock.

 

The Company has been notified by several customers that they would be extending payment terms. The Company anticipates that these extended payment terms will be short-term in nature, but they may continue for a longer duration. In the beginning of April, the Company drew down $5.5 million from its revolving credit facility to maintain cash reserves in the event it experiences a substantial shut down of operations, further or extended increase in manufacturing costs or significant exposure to its ability to timely collect its receivables.

 

16

  

 

ITEM 2:MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Forward-looking Statements

 

Some of the statements contained in this Report are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”). These statements are subject to known and unknown risks, uncertainties, and other factors, which may cause our or our industry’s actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to, statements about the Company’s prospects; statements about the potential impact the COVID-19 pandemic may have on the Company’s business, financial condition and results of operations, including with respect to the different markets in which the Company participates, the demand for its products, the well-being and availability of the Company’s employees, the continuing operation of the Company’s locations, delayed payments by the Company’s customers and the potential for reduced or canceled orders, the Company’s efforts to address the pandemic, including regarding the safety of its employees, the maintenance of its facilities and the sufficiency of the Company’s supply chain, inventory, liquidity and capital resources, including increased costs in connection with such efforts, the impact of the pandemic on the businesses of the Company’s suppliers and customers, and the overall impact the pandemic may have on the Company’s financial results in 2020; statements about the Company’s acquisition strategies and opportunities and the Company’s growth potential and strategies for growth; expectations regarding customer demand; expectations regarding the Company’s liquidity and capital resources, including the sufficiency of its cash reserves and the availability of borrowing capacity to fund operations and/or potential future acquisitions; anticipated revenues and the timing of such revenues; expectations about shifting the Company’s book of business to higher-margin, longer-run opportunities; anticipated trends and potential advantages in the different markets in which the Company competes, including the medical, aerospace and defense, automotive, consumer, electronics, and industrial markets, and the Company’s plans to expand in certain of its markets; anticipated advantages the Company expects to realize from its investments and capital expenditures; anticipated advantages to improvements and alterations at the Company’s existing plants; expectations regarding the Company’s manufacturing capacity, operating efficiencies, and new production equipment; statements about new product offerings and program launches; statements about the Company’s acquisition and integration of Dielectrics and the synergies and other benefits anticipated in connection with the Dielectrics business; the Company’s participation and growth in multiple markets; its business opportunities; and any indication that the Company may be able to sustain or increase its sales, earnings or earnings per share, or its sales, earnings or earnings per share growth rates.

 

Investors are cautioned that such forward-looking statements involve risks and uncertainties that could adversely affect the Company’s business and prospects, and otherwise cause actual results to differ materially from those anticipated by such forward-looking statements, or otherwise, including without limitation: the severity and duration of the COVID-19 pandemic and its impact on the markets in which the Company participates, including its impact on the Company’s customers, suppliers and employees, as well as the U.S. and worldwide economies; the timing, scope and effect of further governmental, regulatory, fiscal, monetary and public health responses to the COVID-19 pandemic; risks and uncertainties associated with the COVID-19 pandemic and its impact on the Company’s business, financial condition and results of operations, including risks relating to decreased, including substantially decreased, demand for the Company’s products; risks relating to the potential closure of any of the Company’s facilities or the unavailability of key personnel or other employees; risks that the Company’s inventory, cash reserves, liquidity or capital resources may be insufficient; risks relating to delayed payments by our customers and the potential for reduced or canceled orders; risks relating to the increased costs associated with the Company’s efforts to respond to the pandemic; risks relating to the Company’s acquisition and integration of Dielectrics; risks associated with the identification of suitable acquisition candidates and the successful, efficient execution of acquisition transactions, the integration of any such acquisition candidates, the value of those acquisitions to our customers and shareholders, and the financing of such acquisitions; risks related to our indebtedness and compliance with covenants contained in our financing arrangements, and whether any available financing may be sufficient to address our needs; risks associated with efforts to shift the Company’s book of business to higher-margin, longer-run opportunities; risks associated with the Company’s entry into and growth in certain markets; risks and uncertainties associated with seeking and implementing manufacturing efficiencies and implementing new production equipment; risks and uncertainties associated with growth of the Company’s business and increases to sales, earnings and earnings per share; and risks associated with new product and program launches. Accordingly, actual results may differ materially.

 

17

  

 

In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “potential,” and similar expressions intended to identify forward-looking statements. Our actual results could be different from the results described in or anticipated by our forward-looking statements due to the inherent uncertainty of estimates, forecasts, and projections, and may be materially better or worse than anticipated. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Forward-looking statements represent our estimates and assumptions only as of the date of this Report. We expressly disclaim any duty to provide updates to forward-looking statements, and the estimates and assumptions associated with them, after the date of this Report, in order to reflect changes in circumstances or expectations, or the occurrence of unanticipated events, except to the extent required by applicable securities laws. All the forward-looking statements are qualified in their entirety by reference to the factors discussed above and under “Risk Factors” set forth in Part I Item 1A of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, as well as the risks and uncertainties discussed elsewhere in this Report, including without limitation any risks and uncertainties included elsewhere in this “Management's Discussion and Analysis of Financial Condition and Results Of Operations” portion of this Report, or under “Risk Factors” in Part II Item 1A of this report. We qualify all of our forward-looking statements by these cautionary statements. We caution you that these risks are not exhaustive. We operate in a continually changing business environment and new risks emerge from time to time.

 

Unless the context requires otherwise, the terms “we”, “us”, “our”, or “the Company” refer to UFP Technologies, Inc. and its consolidated subsidiaries.

 

Overview

 

UFP Technologies is an innovative designer and custom manufacturer of components, subassemblies, products and packaging primarily for the medical market. Utilizing highly specialized foams, films and plastics, the Company converts raw materials through laminating, molding, radio frequency welding and fabricating techniques. The Company is diversified by also providing highly engineered solutions to customers in the aerospace & defense, automotive, consumer, electronics and industrial markets. The Company consists of a single operating and reportable segment.

 

Sales for the Company for the three-month period ended March 31, 2020 grew 2.0% to $48.3 million from $47.3 million in the same period last year due to strong growth in sales to the customers in the medical market. Streamlined manufacturing operations and a better mix of business enabled us to improve gross margins to 26.6% for the three-month period ended March 31, 2020, from 26.4% in the same period last year. Operating income for the three-month period ended March 31, 2020 decreased to $5.1 million from $5.3 million in the same period last year due primarily to higher selling, general and administrative expense, while net income for the three-month period ended March 31, 2020 increased to $3.9 million from $3.7 million in the same period last year.

 

Our current strategy includes further organic growth and growth through strategic acquisitions.

 

Recent Developments

 

COVID-19

 

Our operations expose us to risks associated with the COVID-19 pandemic. Although the COVID-19 pandemic did not materially impact our first quarter results, it has since more significantly impacted our operations. While all of our factories are deemed essential, not all of our customers’ operations are essential and, therefore, demand for product has been negatively impacted, especially in the automotive and consumer markets, where the impact has been substantial. Partially mitigating this are increased orders from certain customers in the medical market. The COVID-19 pandemic has also impacted the cost of manufacturing our goods, including higher labor costs, maintenance costs and manufacturing inefficiencies due to employee absenteeism and significantly enhanced cleaning and sterilization. With regard to our supply chain, there has thus far been minimal disruption in the availability of raw materials, as most of our major suppliers have also been deemed to be essential businesses. However, to mitigate risk, we have increased purchases of raw materials to establish safety stock.

 

We have been notified by several customers that they would be extending payment terms. We anticipate that these extended payment terms will be short-term in nature, but they may continue for a longer duration. In the beginning of April, we drew down $5.5 million from our revolving credit facility to maintain cash reserves in the event we experience a substantial shut down of operations, further or extended increase in manufacturing costs or significant exposure to our ability to timely collect receivables.

 

18

  

 

COVID-19 has spread across the country to areas in which our products are designed, manufactured, distributed or sold. Authorities in states in which we do business have implemented numerous measures to stall the spread of COVID-19, including travel bans and restrictions, quarantines, curfews, shelter in place orders, and business shutdowns. These measures have impacted and will likely further impact us, our customers, consumers, employees, suppliers and other third parties with whom we do business. There is considerable uncertainty regarding how these and any future measures in response to the pandemic will impact our business, including whether and to what extent they will result in further changes in demand for our products, further increases in operating costs (whether as a result of changes to our supply chain or increases in employee or manufacturing costs). Any continued reduced demand for our products due, for example, to reduced need for packaging for consumer and electronic goods, reduced need for components for medical devices, such as those used in elective procedures, reduced need for automobile components, etc., as well as continued economic uncertainty, could adversely and materially affect our business, financial condition and results of operations, as well as those of our customers, resulting in customers’ inability to pay for our products and reduced or canceled orders of our products. Such adverse changes in our customers’ financial condition may also result in our recording impairment charges for our inability to recover or collect any accounts receivable or owned or leased assets.

 

The COVID-19 pandemic and associated economic disruptions have had, and we believe will continue to have, negative effects on our operating results, cash flows and financial condition. While we began to experience these effects towards the end of March, we expect the effects on our financial results in the second and third fiscal quarters will be more significant. Our financial results may be materially adversely impacted by COVID-19 in future periods, as well. While we have developed and implemented and continue to develop and implement health and safety protocols, business continuity plans and crisis management protocols in an effort to try to mitigate the negative impact of COVID-19 on our employees and our business, we believe the extent of the impact of the pandemic on our business and financial results will depend on future developments that are highly uncertain and cannot be predicted, and which may vary by market, including the duration and scope of the pandemic, its severity, economic conditions during and after the pandemic, governmental actions that have or may be taken in response to the pandemic, changes in customer behavior in response to the pandemic, and how quickly and to what extent more predictable economic and operating conditions can resume. As a result, we anticipate that COVID-19 driven demand disruptions and related events will negatively affect our financial results in 2020.

 

Coronavirus Aid, Relief, and Economic Security Act

 

The CARES Act was enacted on March 27, 2020 in the United States. The CARES Act and related notices include several significant provisions, including delaying certain payroll tax payments and estimated income tax payments that we expect to defer to future periods. We do not currently expect the CARES Act to have a material impact on our financial results, including on our annual estimated effective tax rate, or on our liquidity. We will continue to monitor and assess the impact the CARES Act may have on our business and financial results.

 

Results of Operations

 

Sales

 

Sales for the three-month period ended March 31, 2020 increased 2.0% to $48.3 million from $47.3 million in the same period in 2019. The increase in sales for the three-month period ended March 31, 2020 was primarily due to increased sales to the medical market of 16.4%, partially offset by decreases in sales to customers in the aerospace and defense, automotive and, collectively, consumer, industrial and electronics markets of 23.2%, 19.8% and 20.2%, respectively. The increased sales to the medical market was primarily due to continued growth in programs at Dielectrics. The decreased sales to customers in the aerospace and defense market was primarily due to the timing of orders pursuant to government contracts. The decline in sales to the automotive market was due, in part, to our customers’ forecasted decreased demand due to industry shutdowns associated with the COVID19 pandemic. The decline in sales to all other markets was primarily due to reduced demand for molded fiber protective packaging.

 

Gross Profit

 

Gross profit as a percentage of sales (“gross margins”) increased to 26.6% for the three-month period ended March 31, 2020 from 26.4% in the same period in 2019. As a percentage of sales, material and labor costs collectively decreased 0.5%, while overhead increased 0.3%. The decrease in collective material and labor costs as a percentage of sales is primarily due to gains in manufacturing efficiencies resulting from continuous improvement initiatives and an improvement in the overall book of business. The increase in overhead as a percentage of sales was primarily due to increased indirect labor to support anticipated long-term growth. We anticipate higher plant maintenance and supply expenses associated with keeping its manufacturing plants clean in light of the COVID19 pandemic.

 

19

  

 

Selling, General and Administrative Expenses

 

Selling, general and administrative expenses (“SG&A”) for the three-month period ended March 31, 2020 increased 7.0% to $7.8 million from $7.2 million in the same period in 2019. As a percentage of sales, SG&A for the three-month period ended March 31, 2020 increased to 16.1% from 15.3% in the same period in 2019. The increase in SG&A was largely attributable to an increase in stock-based equity awards of approximately $250 thousand and an increase in bad debt expense of approximately $130 thousand from the same period in 2019 due, in part, to the anticipated impact of the COVID19 pandemic on our customers.

 

Interest Income and Expense

 

We had net interest expense of approximately $16 thousand and $231 thousand for the three-month periods ended March 31, 2020 and 2019, respectively. The decrease in net interest expense is due to a reduction in the outstanding balance of debt.

 

Other Expense

 

We had other expense of approximately $327 thousand and $239 thousand for the three-month periods ended March 31, 2020 and 2019, respectively. This increase is due to an increase in the fair value of the swap liability which was caused by interest rate reductions enacted during the first quarter as well as lower anticipated future rate increases. Should we choose to keep the swap for the full five-year term, the cumulative net impact to the income statement due to changes in fair value will be zero.

 

Income Taxes

 

We recorded tax expense of approximately 17.8% and 21.9% of income before income tax expense for the three-month periods ended March 31, 2020 and 2019, respectively. The decrease in the effective tax rate was primarily due to higher anticipated research and development tax credits than those anticipated at this time last year.

 

Liquidity and Capital Resources

 

We generally fund our operating expenses, capital requirements, and growth plan through internally generated cash and bank credit facilities.

 

Cash Flows

 

Net cash provided by operations for the three-month period ended March 31, 2020 was approximately $4.7 million and was primarily a result of net income generated of approximately $3.9 million, depreciation and amortization of approximately $2.1 million, share-based compensation of approximately $0.5 million, an increase in deferred taxes of approximately $0.4 million, a decrease in refundable income taxes of approximately $0.3 million, a decrease in other assets of approximately $0.2 million, a net increase in accounts payable and accrued expenses of approximately $0.6 million, due to the timing of vendor payments and in the ordinary course of business, and an increase in other liabilities of approximately $0.1 million. These cash inflows and adjustments to income were partially offset by an increase in accounts receivable of approximately $0.8 million primarily due to increased sales in the last two months of the first quarter of 2020 over the same period of the fourth quarter of 2019, an increase in inventory of approximately $2.0 million due to restocking to historical levels and for expected safety stock needs, an increase in prepaid expenses of approximately $0.5 million, and a decrease in deferred revenue of approximately $0.1 million.

 

Net cash used in investing activities during the three-month period ended March 31, 2020 was approximately 1.0 million and was primarily the result of additions of manufacturing machinery and equipment across the Company.

 

Net cash used in financing activities was approximately $0.1 million during the three-month period ended March 31, 2020, resulting from payments for statutory withholding for stock options exercised and restricted stock units vested of approximately $0.5 million, partially offset by net proceeds received upon stock options exercises of approximately $0.4 million.

 

Outstanding and Available Debt

 

On February 1, 2018, the Company, as the borrower, entered into an unsecured $70 million Amended and Restated Credit Agreement (the “Amended and Restated Credit Agreement”) with certain of our subsidiaries (the “Subsidiary Guarantors”) and Bank of America, N.A., in its capacity as the initial lender, Administrative Agent, Swingline Lender and L/C Issuer, and certain other lenders from time to time party thereto. The Amended and Restated Credit Agreement amends and restates our prior credit agreement.

 

20

  

 

The credit facilities under the Amended and Restated Credit Agreement (the “Amended and Restated Credit Facilities”) consist of a $20 million unsecured term loan to the Company and an unsecured revolving credit facility, under which we may borrow up to $50 million.  The Amended and Restated Credit Facilities mature on February 1, 2023.  The proceeds of the Amended and Restated Credit Agreement may be used for general corporate purposes, as well as permitted acquisitions. Our obligations under the Amended and Restated Credit Agreement are guaranteed by the Subsidiary Guarantors.

 

The Amended and Restated Credit Facilities call for interest of LIBOR plus a margin that ranges from 1.0% to 1.5% or, at the discretion of the Company, the bank’s prime rate less a margin that ranges from 0.25% to zero. In both cases the applicable margin is dependent upon Company performance. Under the Amended and Restated Credit Agreement, we are subject to a minimum fixed-charge coverage financial covenant as well as a maximum total funded debt to EBITDA financial covenant.  The Amended and Restated Credit Agreement contains other covenants customary for transactions of this type, including restrictions on certain payments, permitted indebtedness and permitted investments.  As of March 31, 2020 there were no amounts outstanding under the Amended and Restated Credit Facilities other than $0.7 million in standby letters of credit outstanding drawable as a financial guarantee on worker’s compensation insurance policies. As of March 31, 2020, the applicable interest rate was approximately 1.99%. The Company was in compliance with all covenants under the Amended and Restated Credit Agreement.

 

Derivative Financial Instruments

 

We use interest-rate-related derivative instruments to manage its exposure related to changes in interest rates on our variable-rate debt instruments. We do not enter into derivative instruments for any purpose other than cash flow hedging. We do not speculate using derivative instruments. By using derivative financial instruments to hedge exposures to changes in interest rates, we expose ourselves to credit risk and market risk. Credit risk is the failure of the counterparty to perform under the terms of the derivative contract. When the fair value of a derivative contract is positive, the counterparty owes the Company, which creates credit risk for us. When the fair value of a derivative contract is negative, the Company owes the counterparty and, therefore, we are not exposed to the counterparty’s credit risk. We minimize counterparty credit risk in derivative instruments by entering into transactions with carefully selected major financial institutions based upon their credit profile. Market risk is the adverse effect on the value of a derivative instrument that results from a change in interest rates. The market risk associated with interest-rate contracts is managed by establishing and monitoring parameters that limit the types and degree of market risk that may be undertaken. We assess interest rate risk by identifying and monitoring changes in interest rate exposures that may adversely impact expected future cash flows and by evaluating hedging opportunities. Our debt obligations expose us to variability in interest payments due to changes in interest rates. We believe that it is prudent to limit the variability of a portion of our interest payments. To meet this objective, in connection with the term loan under the Amended and Restated Credit Agreement, we entered into a $20 million, 5-year interest rate swap agreement under which we receive three-month LIBOR plus the applicable margin and pay a 2.7% fixed rate plus the applicable margin. The swap agreement was established to modify our interest rate exposure by converting interest on the term loan from a variable rate to a fixed rate to hedge against the possibility of rising interest rates during the term of the loan. Because the term loan was repaid in full, the swap agreement no longer serves this purpose and may be canceled by us prior to its expiration date if deemed advantageous. The notional amount was approximately $13.6 million at March 31, 2020. The fair value of the swap as of March 31, 2020 and 2019 was approximately $(624) thousand and $(175) thousand, respectively and is included in other liabilities. Changes in the fair value of the swap are recorded in other expense and were approximately $300 thousand and $239 thousand during the three-months ended March 31, 2020 and 2019, respectively.

 

Future Liquidity

 

We require cash to pay our operating expenses, purchase capital equipment, and to service our contractual obligations. Our principal sources of funds are cash from operations and our $50 million revolving credit facility. We generated cash of approximately $4.7 million from operations during the three months ended March 31, 2020; however we cannot guarantee that our operations will generate cash in future periods. As indicated above, we have been notified by several customers that they intend to extend payment terms due to COVID-19 and, therefore, we anticipate short-term lower operating cash and higher working capital needs. On April 1, 2020 we drew down $5.5 million from our revolving credit facility. Our longer-term liquidity is contingent upon future operating performance and further draws on our revolving credit facility are possible.

 

21

  

 

Throughout fiscal 2020, we plan to continue to add capacity to enhance operating efficiencies in our manufacturing plants. We may consider additional acquisitions of companies, technologies, or products that are complementary to our business. We believe that our existing resources, including our revolving credit facility, together with cash expected to be generated from operations and funds expected to be available to us through any necessary equipment financings and additional bank borrowings, will be sufficient to fund our cash flow requirements, including capital asset acquisitions, through the next twelve months.

 

Stock Repurchase Program

 

On June 16, 2015, we announced that our Board of Directors authorized the repurchase of up to $10.0 million of our outstanding common stock. Under the program, we are authorized to repurchase shares through Rule 10b5-1 plans, open market purchases, privately negotiated transactions, block purchases or otherwise in accordance with applicable federal securities laws, including Rule 10b-18 of the Securities Exchange Act of 1934. The stock repurchase program will end upon the earlier of the date on which the plan is terminated by the Board or when all authorized repurchases are completed. The timing and amount of stock repurchases, if any, will be determined based upon our evaluation of market conditions and other factors. The stock repurchase program may be suspended, modified, or discontinued at any time, and we have no obligation to repurchase any amount of its common stock under the program. We did not repurchase any shares of our common stock under this program in the first three months of 2020. Through March 31, 2020, we repurchased a total of 29,559 shares of our common stock under this program at a cost of approximately $587 thousand. At March 31, 2020, approximately $9.4 million was available for future repurchases of our common stock under this authorization.

 

Commitments and Contractual Obligations

 

There have been no material changes outside the ordinary course of business to our contractual obligations and commitments, as disclosed in our Annual Report on Form 10-K for the year ended December 31, 2019.

 

Off-Balance-Sheet Arrangements

 

In addition to operating leases, our off-balance-sheet arrangements include standby letters of credit which are included in our revolving credit facility. As of March 31, 2020, there was approximately $0.7 million in standby letters of credit drawable as a financial guarantee on worker’s compensation insurance policies.

 

 

ITEM 4:CONTROLS AND PROCEDURES

 

As of the end of the period covered by this report (the “Evaluation Date”), the Company’s management, under the supervision and with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, performed an evaluation of the effectiveness of the design and operation of the Company’s “disclosure controls and procedures” (as defined in SEC Rule 13a-15(e) or 15d-15(e)). Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that, as of the Evaluation Date, the Company’s disclosure controls and procedures were effective to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act of 1934, as amended, is (i) recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and (ii) accumulated and communicated to the Company’s management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

 

An evaluation was also performed under the supervision and with the participation of our management, including the Company’s Chief Executive Officer and Chief Financial Officer, of any change in our internal control over financial reporting that occurred during our last fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting. That evaluation did not identify any change in the Company’s internal control over financial reporting that occurred during our latest fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

22

  

 

PART II:OTHER INFORMATION

 

ITEM 1A:RISK FACTORS

 

There have been no material changes from the risk factors previously disclosed in Part 1 - Item 1A of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, other than as described below.

 

Our business and operations have been adversely affected, and our business, financial condition and results of operations could in the future be materially adversely impacted by the COVID-19 pandemic and associated economic disruptions.

 

The pandemic caused by the spread of the novel strain of coronavirus disease 2019 ("COVID-19") has created significant volatility, uncertainty and economic disruption in the markets in which we participate, and our operations expose us to risks associated with the COVID-19 pandemic. Although the COVID-19 pandemic did not materially impact our first quarter results, since the end of the first quarter it has more significantly impacted our operations. Adverse impacts relating to the COVID-19 pandemic that we have already experienced include, among others: decreased demand for certain of our products in the medical market, such as orders for products related to elective surgeries, and a dramatic decrease in demand for products that service our other markets, such as automotive and consumer, as many of our customers’ businesses are currently shut down; increased labor, supply and maintenance costs, as well as manufacturing inefficiencies, as a result of employee attendance issues and enhanced cleaning and other efforts to safeguard our employees and facilities; increased carrying costs associated with the accelerated purchasing of raw materials, to help secure adequate supplies; and extended payment terms imposed by customers. Although we have not yet experienced significant manufacturing or supply chain difficulties as a result of COVID-19, we may in the future. A reduction or interruption in any of our manufacturing processes, or the closure of any of our facilities, could have a material adverse effect on our business. Our insurance coverage may not adequately compensate us for losses incurred as a direct or indirect result of the COVID-19 pandemic.

 

COVID-19 has spread across the country to areas in which our products are designed, manufactured, distributed or sold. Authorities in states in which we do business have implemented numerous measures to stall the spread of COVID-19, including travel bans and restrictions, quarantines, curfews, shelter in place orders, and business shutdowns. As discussed above, these measures have impacted and will likely further impact us, our customers, consumers, employees, suppliers and other third parties with whom we do business. There is considerable uncertainty regarding how these and any future measures in response to the pandemic will impact our business, including whether and to what extent they will result in further changes in demand for our products or further increases in operating costs (whether as a result of changes to our supply chain or increases in employee or manufacturing costs). Any continued reduced demand for our products due, for example, to reduced need for packaging for consumer and electronic goods, reduced need for components for medical devices, such as those used in elective procedures, reduced need for automobile components, etc., as well as continued economic uncertainty, could adversely and materially affect our business, financial condition and results of operations, as well as those of our customers, resulting in customers’ inability to pay for our products and reduced or canceled orders of our products. Such adverse changes in our customers’ financial condition may also result in our recording impairment charges for our inability to recover or collect any accounts receivable or owned or leased assets.

 

In the beginning of April, we drew down $5.5 million from our revolving credit facility to maintain sufficient cash reserves in the event we experience a substantial shut down of operations, further or extended increase in manufacturing costs or significant exposure to our ability to timely collect our receivables. The terms of our Amended and Restated Credit Facilities contain covenants that restrict our ability to engage in certain transactions and, if not met, may impair our ability to respond to changing business and economic conditions. Our Amended and Restated Credit Facilities also require us to satisfy certain financial covenants. Should our future business and operations be significantly impaired by the continuing COVID-19 pandemic and associated economic disruptions or otherwise, we cannot assure that we will remain in compliance with our current financial covenants. In such event, the factors that adversely affect our business may also similarly adversely affect the capital markets, and we cannot assure that we would be able to negotiate alternative covenants or alternative financing on favorable terms, if at all. Our failure to comply with the covenants contained in our Amended and Restated Credit Facilities, including financial covenants, could result in an event of default, which could materially and adversely affect our results of operations and financial condition.

 

The COVID-19 pandemic and associated economic disruptions have had, and we believe will continue to have, negative effects on our operating results, cash flows and financial condition. While we began to experience these effects towards the end of March, we expect the effects on our financial results in the second and third fiscal quarters will be more significant. Our financial results may be materially adversely impacted by COVID-19 in future periods, as well. We believe the extent of the impact of the pandemic on our business and financial results will depend on future developments that are highly uncertain and cannot be predicted, and which may vary by market, including the duration and scope of the pandemic, its severity, economic conditions during and after the pandemic, governmental actions that have or may be taken in response to the pandemic, changes in customer behavior in response to the pandemic, and how quickly and to what extent more predictable economic and operating conditions can resume. As a result, the Company anticipates that COVID-19 driven demand disruptions and related events will negatively affect the Company's financial results in 2020.

 

23

  

 

We refer you to “Management’s Discussion and Analysis of Financial Position and Results of Operations” for additional discussion of the potential impact of the COVID-19 pandemic and associated economic disruptions.

 

ITEM 2:UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

Issuer’s Purchases of Equity Securities

 

On June 16, 2015, the Company issued a press release announcing that its Board of Directors authorized the repurchase of up to $10.0 million of the Company’s outstanding common stock. The Company did not repurchase any shares of its common stock under this program in the first three months of 2020. Through March 31, 2020, the Company had repurchased a total of 29,559 shares of its common stock under this program at a cost of approximately $587 thousand. At March 31, 2020, approximately $9.4 million was available for future repurchases of the Company's common stock under this authorization.

 

 

ITEM 6:EXHIBITS

 

Exhibit No. Description
   
10.1 Form of 2020 CEO Stock Unit Award Agreement (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed with the SEC on February 28, 2020 (SEC File No. 001-12648)). #
10.2 Form of 2020 Stock Unit Award Agreement (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K, filed with the SEC on February 28, 2020 (SEC File No. 001-12648)). #
31.1 Rule 13a-14(a)/15d-14(a) Certification of the Chief Executive Officer.*
31.2 Rule 13a-14(a)/15d-14(a) Certification of the Chief Financial Officer.*
32.1 Certifications pursuant to 18 U.S.C., Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**
101.INS XBRL Instance Document.*
101.SCH XBRL Taxonomy Extension Schema Document.*
101.CAL XBRL Taxonomy Calculation Linkbase Document.*
101.DEF XBRL Taxonomy Extension Definition Linkbase Document.*
101.LAB XBRL Taxonomy Label Linkbase Document.*
101.PRE XBRL Taxonomy Presentation Linkbase Document.*

__________________

*Filed herewith.
**Furnished herewith.

# Indicates management contract or compensatory plan or arrangement.

 

 

 

24

  

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

UFP TECHNOLOGIES, INC.

 

Date: May 8, 2020 By:   /s/ R. Jeffrey Bailly
    R. Jeffrey Bailly
    Chairman, Chief Executive Officer,
President, and Director
(Principal Executive Officer)
     
Date: May 8, 2020 By:   /s/ Ronald J. Lataille
    Ronald J. Lataille
Chief Financial Officer
(Principal Financial Officer)
     

 

 

 

 

 

 

 

 

 

 

 

25